Navignostics AG
Pioneering spatial proteomics and AI for precision oncology
Navignostics is a precision oncology company pioneering the use of spatial single-cell proteomics to transform cancer diagnostics and treatment selection. Founded in 2022 as a spin-off from the University of Zurich’s Bodenmiller Lab, Navignostics uses 40-plex spatial proteomics to guide personalized cancer treatment today, while generating the Dx-grade ground truth that trains our AI to deliver the same insights from the low-cost slides already in every pathology lab. Finding the right drug for every patient.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
27.11.2025
Swiss Technology Award 2025: Nanotechnology and precision medicine lead the way (startupticker.ch)
11.09.2025
Das Finalisten-Feld des Swiss Technology Award 2025 (startupticker.ch)
09.07.2025
Key milestones bring startups close to launching vital medical solutions (startupticker.ch)
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Leaders Biotech
Navignostics AG
Pioneering spatial proteomics and AI for precision oncology
Website:
www.navignostics.com
Headquarter:
Horgen
Foundation Date:
March 2022
Technology:
- Biotech
Sectors:
- Big Data
- Biotech
- Cancer
- Digital Health
- Diagnostics
- Machine Learning / AI
Support received
